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Mammalian heart development is orchestrated by a com-plex interplay of cardiac transcription factors, muta-
tions in which are often associated with congenital heart 
defects.1 The transcription factor Tbx20 (T-box 20) is ex-
pressed in developing and adult cardiomyocytes, as well as 
pharyngeal endoderm, cardiac progenitors, endothelium, 
and endocardium.2–4 Mutations in TBX20 are associated 
with congenital heart defects, including septal defects and 
cardiomyopathies.5–9
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Rationale: Mutations in the transcription factor TBX20 (T-box 20) are associated with congenital heart disease. 
Germline ablation of Tbx20 results in abnormal heart development and embryonic lethality by embryonic day 9.5. 
Because Tbx20 is expressed in multiple cell lineages required for myocardial development, including pharyngeal 
endoderm, cardiogenic mesoderm, endocardium, and myocardium, the cell type–specific requirement for TBX20 
in early myocardial development remains to be explored.
Objective: Here, we investigated roles of TBX20 in midgestation cardiomyocytes for heart development.
Methods and Results: Ablation of Tbx20 from developing cardiomyocytes using a doxycycline inducible cTnTCre 
transgene led to embryonic lethality. The circumference of developing ventricular and atrial chambers, and in 
particular that of prospective left atrium, was significantly reduced in Tbx20 conditional knockout mutants. Cell 
cycle analysis demonstrated reduced proliferation of Tbx20 mutant cardiomyocytes and their arrest at the G1-S 
phase transition. Genome-wide transcriptome analysis of mutant cardiomyocytes revealed differential expression 
of multiple genes critical for cell cycle regulation. Moreover, atrial and ventricular gene programs seemed to 
be aberrantly regulated. Putative direct TBX20 targets were identified using TBX20 ChIP-Seq (chromatin 
immunoprecipitation with high throughput sequencing) from embryonic heart and included key cell cycle genes 
and atrial and ventricular specific genes. Notably, TBX20 bound a conserved enhancer for a gene key to atrial 
development and identity, COUP-TFII/Nr2f2 (chicken ovalbumin upstream promoter transcription factor 2/
nuclear receptor subfamily 2, group F, member 2). This enhancer interacted with the NR2F2 promoter in human 
cardiomyocytes and conferred atrial specific gene expression in a transgenic mouse in a TBX20-dependent manner.
Conclusions: Myocardial TBX20 directly regulates a subset of genes required for fetal cardiomyocyte proliferation, 
including those required for the G1-S transition. TBX20 also directly downregulates progenitor-specific genes 
and, in addition to regulating genes that specify chamber versus nonchamber myocardium, directly activates 
genes required for establishment or maintenance of atrial and ventricular identity. TBX20 plays a previously 
unappreciated key role in atrial development through direct regulation of an evolutionarily conserved COUPT-FII 
enhancer.  (Circ Res. 2018;123:428-442. DOI: 10.1161/CIRCRESAHA.118.311339.)
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After formation of the developing heart tube, the heart grows 
by addition of cardiac progenitor cells. In addition, cardiomyo-
cyte proliferation between embryonic day (E) 9.5 to E12.5 makes 
major contributions to growth of chamber myocardium.10 Tbx20 
global mutants exhibit decreased cardiomyocyte proliferation 
and arrest development at E9.5, with hypoplastic, unlooped 
hearts.11–13 Initially, defective proliferation was attributed to ec-
topic expression of Tbx2 throughout mutant hearts, which sup-
presses proliferation in cardiomyocytes.11–14 However, combined 
loss of Tbx20 and Tbx2 does not rescue the hypoplastic heart 
phenotype, indicating that TBX20 regulates additional pathways 
to control cardiomyocyte proliferation, independent of Tbx2.15 
Although these studies demonstrated a key role for TBX20 in 
regulating cardiomyocyte proliferation, whether this requirement 
was cell autonomous has not been addressed, as TBX20 is ex-
pressed in multiple nonmyocardial cell lineages that are required 
for cardiomyocyte proliferation and development. Although re-
cent studies have addressed roles of TBX20 in subsets of cellular 
lineages during heart development,16,17 and in adult cardiomyo-
cytes,18,19 no study has yet addressed the function of TBX20 in 
embryonic cardiomyocytes that form the developing cardiac 
chambers. Thus, temporal and cell autonomous requirements for 
TBX20 in cardiomyocytes during heart formation remain to be 
explored. Additionally, a comprehensive view of direct down-
stream targets of TBX20 in fetal cardiomyocytes is lacking.
Here, using an inducible cardiomyocyte-specific Cre mouse 
line, we demonstrated that TBX20 is required within midgesta-
tion cardiomyocytes to drive multiple aspects of cardiomyo-
cyte development. TBX20 directly activated genes required for 
myocyte proliferation, directly repressed progenitor-specific 
genes, and specified ventricular and atrial identity through 
both gene repression and activation. Notably, we uncovered 
a pivotal role for TBX20 in atrial development and identity, 
identifying the gene encoding the nuclear hormone receptor 
transcription factor COUP-TFII/NR2F2 (chicken ovalbumin 
upstream promoter transcription factor 2/nuclear receptor sub-
family 2, group F, member 2) as a direct downstream target. 
A long-range enhancer for COUP-TFII bound by TBX20 was 
conserved between mouse and human and drove atrial specific 
expression in mouse embryos. Our work highlights myocyte 
autonomous requirements for TBX20 and comprehensively 
identifies gene networks directly regulated by TBX20 in this 
context. Additionally, we uncover transcriptional mechanisms 
regulating COUP-TFII expression and reveal a previously un-
appreciated key role for TBX20 in atrial development.
Methods
Genome-wide sequencing data have been made publicly available at 
the ArrayExpress database and can be accessed at https://www.ebi.
ac.uk/arrayexpress/experiments/E-MTAB-5596/.
Other data and analytical methods are available from the corre-
sponding authors on reasonable request.
Mouse Strains and Experiments
Animal experiments were conducted according to protocols approved 
by Institutional Animal Care and Use Committee at University of 
California, San Diego or University of Chicago. Mice were main-
tained on BlackSwiss (NIHBL(S); Taconic Biosciences) background. 
Tbx20loxP, Tbx20-GFP, Tnnt2-rtTA;TetO-Cre, and Rosa26 flox-stop-
flox tdTomato (R26-tdTom) mouse lines were as described.12,19–21 
Cardiomyocyte-specific Tbx20 conditional mutants (Tbx20 con-
ditional knockout mutant [cKO]; Tnnt2-rtTA;TetO-Cre;Tbx20loxP/
loxP) and controls (control; Tnnt2-rtTA;TetO-Cre;Tbx20wt/loxp) were 
generated by breeding Tnnt2-rtTA;TetO-Cre;Tbx20+/loxp males with 
Tbx20loxP/loxP or Tbx20loxP/loxP;R26tdTom/tdTom females. Cre expression was 
induced by doxycycline (MP Biomedicals; catalog number: 198955; 
1 mg/mL) in water prepared fresh daily to pregnant females from 
E8.5 onward. All experiments were performed using somite stage 
and size-matched embryo pairs, images shown are representative ex-
amples of experiments with n≥3 biological replicates.
Quantification Experiments and Statistical 
Analysis
Cardiac chamber size was quantified by perimeter measurements in 
every fourth section (10 μm). 200 μL 5-Ethynyl-2’-deoxyuridine 
(EdU; Molecular probes; 3g/L) was injected intraperitoneally in 
Nonstandard Abbreviations and Acronyms
AVC atrioventricular canal
cKO conditional knock out mutant
EdU 5-ethynyl-2’-deoxyuridine
OFT outflow tract
qPCR quantitative polymerase chain reaction
Novelty and Significance
What Is Known?
• Mutations in the t-box transcription factor TBX20 (T-box 20) are associ-
ated with a diverse range of congenital heart defects including septal 
defects and left ventricular noncompaction.
• In mice, TBX20 is required for cardiogenesis and during embryonic 
development is expressed in multiple cell types, including cardiomyo-
cytes, endocardial cells, and endodermal cells.
• The functions of TBX20 in developing cardiomyocytes and the mecha-
nisms by which mutations in TBX20 contribute to congenital heart dis-
ease are not fully understood.
What New Information Does This Article Contribute?
• TBX20 is required during midgestation to drive multiple aspects of car-
diomyocyte development.
• TBX20 directly activates genes required for myocyte proliferation and 
promotes G1 to S progression of the cardiomyocyte cell cycle.
• TBX20 has a key role in atrial development and identity.
Despite the recognition that TBX20 is a key factor driving heart 
development and function, its roles in embryonic cardiomyocytes 
have not been fully explored. Cardiomyocyte specific functions 
of TBX20 may underlie the association of TBX20 with congenital 
heart defects such as septal defects and left ventricular noncom-
paction. Using a cardiomyocyte-specific loss-of-function mouse 
model, we revealed cell-autonomous functions of TBX20 driving 
cardiomyocyte proliferation and chamber patterning, including in 
the left atria. The roles of this transcriptional regulator are more 
diverse and context dependent than previously appreciated.
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pregnant females 2 hours before embryo isolation. EdU incorpora-
tion was quantified using Volocity software. FlowJo software was 
used for cell cycle analysis on tdTom+ cardiomyocytes. Data are ex-
pressed as means±SEM, for n≥3 biological replicates (actual number 
of biological replicates for each experiment stated in figure legends). 
Mann–Whitney U test was used to compare 2 groups, reporting as-
ymptotic 2-tailed significance P values. Cell cycle quantification and 
EdU incorporation counts were analyzed using negative binomial re-
gression using SPSS25 software (Online Tables V through X). Post 
hoc tests for negative binomial regression were performed using the 
Bonferroni correction. P<0.05 was considered significant.
Promotor Capture Chromosome Conformation 
Capture With High-Throughput Sequencing in 
Human Cardiomyocytes
Human cardiomyocyte cells were generated precisely as described 
before using induced pluripotent stem cell line 19101.22 Promoter 
capture chromosome conformation capture with high-throughput 
sequencing was performed by combining in situ chromosome con-
formation capture with high-throughput sequencing with an oligo 
hybridization step as detailed in the Online Data Supplement.
Results
TBX20 Is Required in Cardiomyocytes During 
Cardiac Chamber Formation
TBX20 is expressed in cardiomyocytes throughout heart devel-
opment.2,11–13,23 Early lethality of systemic Tbx20 mutants pre-
vents analysis of its role in cardiomyocytes at later stages. To 
study roles of TBX20 in midgestation cardiomyocytes, we ab-
lated Tbx20 from cardiomyocytes after E8.5 using doxycycline 
inducible Tnnt2-rtTA;TetO-Cre21 (Online Figure IA). After 
doxycycline administration, R26-tdTomato expression demon-
strated efficient cardiomyocyte-specific Cre-mediated excision 
(Online Figure IB through ID). Significant ablation of Tbx20 
exon 2 was observed by quantitative polymerase chain reac-
tion (qPCR) as early as E9.5 (Online Figure IE). Embryos with 
heterozygous cardiomyocyte-specific deletion of Tbx20 were 
recovered at expected Mendelian ratios at all stages examined. 
However, by E14.5, embryos with homozygous cardiomyo-
cyte-specific deletion of Tbx20 (Tbx20 cKOs) were markedly 
reduced (P=0.042; Online Table I), suggesting an ongoing re-
quirement for TBX20 in midgestation cardiomyocytes.
Analysis of gross external morphology revealed that Tbx20 
cKO and wild-type control embryos were of similar size and 
shape at E11.5 and earlier stages (Figure 1). Histological ex-
amination revealed that at E9.5, Tbx20 cKO hearts were prop-
erly looped and visually indistinguishable from control hearts. 
However, at E10.5 and E11.5, overall heart size appeared reduced 
in Tbx20 cKO mutants. Most notably, left atrial size in mutant 
hearts was severely reduced (Figures 1 and 2). Circumferential 
measurements of cardiac chambers confirmed that left atrium and 
left ventricle were significantly smaller, whereas reduced sizes of 
right atrium and right ventricle were not statistically significant 
(Figure 2I). Moreover, Tbx20 cKO hearts had underdeveloped 
atrial and interventricular septa, and venous valves of Tbx20 cKO 
hearts were smaller at E10.5 and thinner at E11.5 when compared 
with controls (Figure 2). Tbx20 cKO outflow tracts (OFTs) ap-
peared shorter at E10.5 and E11.5 (Figure 1J through 1X). Taken 
together, these results revealed that TBX20 was required in car-
diomyocytes for multiple aspects of cardiac development, includ-
ing cardiac chamber development and cardiac septation.
TBX20 Is Required for Cardiomyocyte 
Proliferation
The observation that loss of TBX20 in cardiomyocytes led to 
a hypoplastic heart and a concomitant decrease in chamber 
size led us to investigate cardiomyocyte proliferation. EdU 
incorporation was quantified in Tnnt2-rtTA;TetO-Cre;R26+/
tdTom
 lineage traced cardiomyocytes at E9.5, E10.5, and E11.5 
(Figure 3A through 3E). At all stages examined, cardiomyo-
cyte proliferation was significantly decreased in Tbx20 mu-
tant hearts compared with cardiomyocytes of somite-matched 
control littermates (Online Tables IX and X). To understand 
whether proliferation was affected similarly in all chambers, 
EdU incorporation rates were quantified per compartment in 
E10.5 hearts. Proliferation of cardiomyocytes was decreased 
in developing chambers and OFT, with left atrial cardiomy-
ocytes displaying the strongest reduction (Online Figure II; 
Online Table VI). In contrast, proliferation of nonmyocytes 
was comparable between mutants and controls (Online Figure 
II). Furthermore, reduced heart size was not associated with 
programmed cell death as indicated by comparable (low) lev-
els of cleaved caspase 3 immunostaining in E10.5 mutant and 
control hearts (data not shown).
TBX20 Is Required for Cardiomyocyte G1 to S 
Phase Transition
Our phenotypic analysis, including quantification of chamber 
size and proliferation, were consistent with a role for Tbx20 in 
cardiomyocyte cell division. To gain insight into the mecha-
nisms of TBX20-mediated cardiomyocyte cell cycle regula-
tion, we conducted an analysis of cardiomyocyte cell cycle 
progression (Online Tables XII and XIII). Fluorescence ac-
tivated cell sorting analysis of EdU incorporation and DNA 
content demonstrated that a higher percentage of Tbx20 cKO 
cardiomyocytes were in G1 phase, whereas a lower percentage 
of Tbx20 cKO cardiomyocytes were in S phase relative to con-
trols, suggesting defective G1 to S phase progression in Tbx20 
mutant cardiomyocytes (Figure 3F and 3G; Online Tables XII 
and XIII). These data suggested that TBX20 was required for 
cardiomyocyte cell cycle progression in cardiomyocytes.
TBX20 Regulates Pathways Associated With Cell 
Cycle and Cardiac Morphogenesis
To further understand genetic pathways regulated by TBX20 
in cardiomyocytes, we performed RNA-Seq (RNA sequenc-
ing) on fluorescence activated cell sorting–purified cardio-
myocytes from E11.5 Tbx20 cKO and somite stage–matched 
littermate control hearts (Online Figure IIIA). Of 1478 differ-
entially expressed genes (fold change >1.2×; P adjusted <0.1), 
816 were downregulated in Tbx20 cKO cardiomyocytes, and 
expression of 662 genes was increased compared with control 
cardiomyocytes (Online Table III).
Next, we performed Gene Ontology term enrichment 
analysis on differentially expressed genes. We grouped Gene 
Ontology terms in major categories, compared occurrence of 
these categories across gene sets, and observed a clear-cut dif-
ference between up- and downregulated genes in Tbx20 mu-
tant cardiomyocytes (Figure 4A). Downregulated genes were 
predominantly involved in cell cycle, contraction, and en-
ergy metabolism, whereas upregulated genes were primarily 
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involved in general developmental pathways, neuronal func-
tion, and heart development.
Downregulated genes within the cell cycle functional cat-
egory included Cdc6 (cell division cycle 6), Cdt1 (chromatin 
licensing and DNA replication factor 1), and Ccna2 (cyclin 
A2). CDC6 and CDT1 are involved in the formation of the 
prereplication complex that is necessary for DNA replica-
tion.24 CDC6 and CCNA2 activate CDK2 (cyclin-dependent 
kinase 2), which is required during G1 phase of the cell cycle 
for onset of chromosomal DNA replication in mammalian 
cells.25,26 Downregulation of Cdc6, Cdt1, and Ccna2 in Tbx20 
cKO cardiomyocytes was consistent with our observation that 
Figure 1. Cardiac morphology of Tnnt2-rtTA; TetO-Cre; Tbx20 fl/fl mutant embryos and Tnnt2-rtTA; TetO-Cre; Tbx20 +/fl control littermates at E9.5 (A–
H), E10.5 (I–P), and E11.5 (Q–X). From left to right in each row: whole embryo, right side view, ventral view, and left side view of hearts. A indicates atrium; 
cKO, conditional knock out mutant; LA, left atrium; LV, left ventricle; OFT, outflow tract; RA, right atrium; RV, right ventricle; Tbx20, T-box 20; and V, ventricle. 
Dotted line indicates outline of atria as labeled. Bars: left: 1 mm; other parts: 0.2 mm.
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mutant cardiomyocytes displayed decreased G1 to S transition 
and provided support for the hypothesis that TBX20 promotes 
cell cycle progression in midgestation cardiomyocytes.
Genes critical for cardiac development within the group 
of upregulated genes included Tbx2, Isl1 (LIM/homeodomain 
transcription factor Islet1), Fgf10 (fibroblast growth factor 
10), Hopx, Bmp2 (bone morphogenetic protein 2), and Bmp10, 
indicating that TBX20 was essential for directly or indirectly 
regulating genes encoding transcription factor and signaling 
pathways critical for cardiac morphogenesis.
Intersection of RNA-Seq and TBX20 ChIP-Seq 
Reveals Critical Direct Targets of TBX20
TBX20 has a dual role as both a transcriptional activator and 
a repressor.27 In adult heart, each of these functions regu-
lates genes with specialized and distinct molecular roles. To 
identify putative direct targets of TBX20 in midgestation 
cardiomyocytes, we made use of our TBX20 ChIP-Seq (chro-
matin immunoprecipitation with high throughput sequencing) 
analysis in E11.5 hearts and attributed TBX20-bound sites to 
the nearest expressed gene in E11.5 control or Tbx20 cKO 
cardiomyocytes. Next, we overlaid our RNA-Seq data with 
that of our TBX20 ChIP-Seq analysis in E11.5 hearts17 and 
identified 548 genes that were differentially expressed in 
Tbx20 cKO cardiomyocytes and were marked by one or more 
TBX20 binding events in the vicinity of the gene (Figure 4B). 
Functional analysis of these putative direct TBX20 targets 
revealed that TBX20 activated and repressed genes fall into 
distinct categories (Online Figure III). Most notably, TBX20 
directly activated cardiac muscle development and function 
genes and directly repressed other developmental pathways.
Motif Analysis
To investigate potential TBX20 DNA-binding cofactors, we 
scanned TBX20-binding regions associated with differentially 
expressed genes in Tbx20 mutant embryonic cardiomyocytes 
for over-representation of transcription factor-binding sites. 
With this analysis, we found that TBX20-bound regions were 
enriched for DNA-binding motifs of T-box transcription factors, 
GATA type zinc fingers, basic leucine zipper domains (bZIP), 
TEA domain TF (transcriptional enhancer activator domain 
transcription factors) and MADS-box TF (MCM1, agamous, de-
ficiens, serum response factor-Box domain transcription factors; 
Figure 4C). Notably, we did not observe significant differences 
in type of motifs found between upregulated and downregulated 
genes (Online Table IV). These results indicated that TBX20 co-
operated with multiple TFs to stimulate or repress expression of 
target genes but did not provide an explanation as to why some 
genes were repressed and others were activated.
TBX20 Directly Activates Genes Required for 
Cardiomyocyte Proliferation
Decreased proliferation and interrupted cell cycle in Tbx20 
cKO mutant hearts suggested downregulation of genes impor-
tant for cell cycle regulation in cardiomyocytes. In keeping with 
this, identified putative direct targets of TBX20 downregulated 
in Tbx20 cKO myocytes included Cdc6, a gene that regulates 
G1-S cell cycle progression. Putative direct downregulated tar-
gets also included Mycn and Erbb2, each required for myo-
cardial proliferation and essential for heart development.28,29 
Using qPCR, we confirmed downregulation of Cdc6 and Mycn 
at E9.5, whereas Erbb2 was not significantly downregulated 
in E9.5 or E11.5 Tbx20 cKO hearts (Figure 5A). Using in situ 
hybridization, both Mycn and Erbb2 expression seemed down-
regulated in E9.5 and E11.5 Tbx20 cKO ventricles (Figure 5).
TBX20 Directly Represses a Cardiac Progenitor 
Gene Program in Cardiomyocytes
Among upregulated putative direct target genes were an intrigu-
ing number of key second heart field genes, including the Isl1, 
Fgf10, and Hopx (HOP homeobox). Marking subsets of cardiac 
Figure 2. Analysis of cardiac phenotypes and quantification of 
chamber size. A–H, Hematoxylin and eosin–stained sections of Tbx20 
cKO and control hearts at E10.5 (A–D) and E11.5 (E–H). Filled arrowhead: 
primary atrial septum; open arrowhead: interventricular septum; arrow: 
venous valves. I, Circumference measurement of right atrium (RA), left 
atrium (LA), right ventricle (RV), and left ventricle (LV) in Tbx20 cKO and 
control hearts. *P<0.05 Mann–Whitney U test; n=3 biological replicates. AU 
indicates arbitrary units; cKO, conditional knock out mutant; and Tbx20, 
T-box 20. Bars: 0.2 mm (A–H).
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progenitor cells, Isl1, Fgf10, and Hopx are essential for prolif-
eration, survival, and migration of undifferentiated cardiomyo-
cyte progenitors and are downregulated as progenitors enter the 
heart and differentiate toward cardiomyocytes.30–32 To validate 
sustained expression of a cardiac progenitor gene program in 
cardiomyocytes after ablation of Tbx20, RNA in situ hybridiza-
tion was performed for Isl1 and Fgf10. At E11.5, where Isl1 
expression is typically restricted to the distal OFT, in Tbx20 
cKO mutants, Isl1 was expanded into the proximal OFT and 
right ventricle (Figure 6B and 6C). Isl1 upregulation could also 
be detected by qPCR at this stage (Figure 6A). In contrast, and 
despite significant increased RNA levels by RNA-Seq, Fgf10 
transcript levels did not achieve sufficient levels in mutant and 
control hearts to be detectable by RNA in situ (Online Figure 
IVA through IVD). However, Fgf10 was significantly upregu-
lated by qPCR in E11.5 Tbx20 cKO hearts (Online Figure 
IVM). Collectively, these data suggested that TBX20 directly 
represses a subset of cardiac progenitor genes, thereby promot-
ing further differentiation and maturation of cardiomyocytes.
Cardiac Chamber Formation Is Properly Initiated 
in Tbx20 cKO Hearts
After heart tube formation and cardiac looping, cardiac cham-
bers form at the outer curvature of the looped heart. Global 
Tbx20 mutants display gross defects in initiation of chamber 
formation. We assessed whether chamber-specific differentia-
tion patterns were initiated in Tbx20 cKO hearts by analyzing 
expression of molecular markers for chamber myocardial dif-
ferentiation, including potential direct targets Gja5 and Tbx5. 
At early stages examined, E9.5 and E10.5, expression of Gja5 
and Tbx5 was not markedly changed between controls and 
mutants (Online Figure IVE through IVL). We also assessed 
expression of the pan-cardiac marker Nkx2-5 and found that 
its expression was comparable between control and mutants 
(Figure 6E and 6F). The transcriptional repressor Tbx2 that can 
suppress chamber-specific gene expression was upregulated 
in Tbx20 cKO hearts at E9.5 (Online Figure IVM). Together, 
these data suggested that some, but not all, aspects of cardiac 
chamber formation were properly initiated in Tbx20 cKOs.
Figure 3. Proliferation and cell cycle analysis in control and Tbx20 (T-box 20) mutant cardiomyocytes. A–D, 5-Ethynyl-2’-deoxyuridine (EdU) 
incorporation (green) along with tdTomato (red) for Tnnt2-rtTA;TetO-Cre lineage-traced cardiomyocytes and DAPI (4’,6-diamidine-2’-phenylindole 
dihydrochloride; blue) for nuclei. E, Quantification of EdU incorporation in lineage-traced cardiomyocytes. F, Fluorescence activated cell sorting cell cycle 
analysis using EdU incorporation and DNA content (DAPI) in Tbx20 cKO and control lineage–traced cardiomyocytes. Percentage of cells in S phase is 
labeled. G, Quantification of cardiomyocytes per cell cycle stage in Tnnt2-rtTA;TetO-Cre;Tbx20fl/fl (mutant, outer circle) and Tnnt2-rtTA;TetO-Cre;Tbx20+/
fl (control, inner circle) littermates. E and G: n=3 biological replicates; *, P<0.05 based on negative binomial regression analysis. Bars: 0.2 mm (A–D). cKO 
indicates conditional knock out mutant; and Tbx20, T-box 20.
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At E11.5, Tbx5 expression was markedly increased specif-
ically in Tbx20 cKO atria compared with controls (Figure 6D 
and 6E). Embryos lacking Tbx5 have abnormal heart tube for-
mation and hypoplastic atria, whereas overexpression of Tbx5 
inhibits ventricular maturation.33,34 In chicken embryos, Tbx5 
overexpression inhibits myocyte proliferation.35 Therefore, 
overexpression of Tbx5 in Tbx20 cKO atria might contribute 
to reduced atrial proliferation in Tbx20 cKOs, highlighting an 
important role for TBX20 in regulating atrial gene expression.
TBX20 Directly Represses Both Atrioventricular 
Canal and Ventricular Specific Genes Within Atria 
to Establish an Atrial Gene Program
To further explore roles TBX20 might have in regulating 
compartment-specific gene expression, we assessed expres-
sion patterns of other key genes regionally expressed in de-
veloping heart. Bmp2 is expressed within atrioventricular 
canal (AVC) myocardium and OFT and is critical for early 
AVC development and cardiac cushion formation.36,37 BMP2 
activates Tbx2 in AVC myocardium to repress a chamber 
myocardial phenotype and induce cushion development.38 In 
E11.5 Tbx20 cKOs, Bmp2 expression within AVC was un-
altered, but its expression domain was aberrantly extended 
into atrial myocardium (Figure 6F and 6G). Increased Bmp2 
expression in E11.5 Tbx20 cKO cardiomyocytes was con-
firmed by qPCR (Figure 6A). Bmp10 is a critical gene for tra-
beculation and growth of the ventricular wall.39 Expression 
levels of Bmp10 were not affected in ventricles of Tbx20 
cKOs. However, aberrant upregulation of Bmp10 was ob-
served in right atria of mutants (Figure 6H and 6I). Ectopic 
Bmp10 expression in mutant atria did not result in a signifi-
cant increase in overall Bmp10 mRNA levels when qPCR 
were performed on RNA from total cardiomyocytes puri-
fied from E11.5 heart (Figure 6A). However, Bmp10 mRNA 
levels were found to be significantly increased in mutants 
right atria relative to controls when RNA was specifically 
extracted from isolated E11.5 right atrial tissue (Figure 6A). 
Although previous studies have associated upregulation of 
Bmp10 with hypertrabeculated ventricles,40 potential ef-
fects of Bmp10 upregulation in right atrium have not been 
described. Together, these findings suggested that TBX20 
might regulate atrial cardiomyocyte development by directly 
repressing nonatrial genes, including Bmp2 and Bmp10, in 
atrial cardiomyocytes.
Upregulation of Tbx5, Bmp2, or Bmp10 in atria did not 
seem to explain why left atrial proliferation was more se-
verely affected than right atrial proliferation. To investigate 
potential pathways accounting for increased severity of the 
left atrial phenotype, we investigated expression of Pitx2, 
a major regulator of left–right asymmetry in the heart.41 
Our ChIP-Seq data suggested that Pitx2 might be a direct 
TBX20 target. PITX2 inhibits left atrial proliferation, with 
mutants showing right atrial isomerism.42,43 Using in situ 
Figure 4. Gene ontology analysis of differentially expressed genes in embryonic day (E) 11.5 Tbx20 cKO cardiomyocytes vs control littermates. 
A, Gene ontology analysis of differentially expressed genes in Tbx20 cKO cardiomyocytes clustered into functional categories (green: underexpressed; 
red: overexpressed). Length of bars indicate the difference of Gene Ontology enrichment for each category between up- and downregulated genes. B, 
Intersection of RNA-Seq (RNA sequencing) and TBX20 (T-box 20)-GFP (green fluorescent protein) ChIP-Seq (chromatin immunoprecipitation with high 
throughput sequencing) in E11.5 hearts reveals putative direct targets of TBX20 in embryonic cardiomyocytes. C, Top overrepresented TF motifs in TBX20 
ChIP-Seq peaks associated with differentially expressed genes. cKO indicates conditional knock out mutant.
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hybridization, we did not observe differences in Pitx2 ex-
pression levels or pattern in E9.5 or E11.5 mutants (Online 
Figure IVN through IVQ and data not shown). These obser-
vations indicated that left–right differences in Tbx20 cKO 
hearts occurred independently of alterations in Pitx2 mRNA 
expression.
TBX20 Directly Activates Atrial and Ventricular 
Specific Genes to Establish Atrial and Ventricular 
Identity
From our genome-wide transcriptome and ChIP-Seq analy-
sis, we identified multiple putative direct downstream tar-
gets of TBX20 downregulated in cKOs that have critical 
roles in establishing chamber identity, including COUP-
TFII, Hey1, Hey2, and Irx4.44–46 In developing human 
and mouse heart, COUP-TFII is abundantly expressed 
in atria and determines atrial identity by activating atrial 
markers and by repressing ventricular markers.46,47 Using 
qPCR, we confirmed that COUP-TFII was downregulated 
in Tbx20 cKO hearts at E9.5 and E11.5 (Figure 7A). In 
situ hybridization indicated that COUP-TFII expression 
in atria was similar between Tbx20 cKOs and controls at 
E9.5 (Figure 7B). However, at E10.5 and E11.5, COUP-
TFII expression was greatly reduced in Tbx20 cKO atria 
relative to controls. The atrial specific gene Hey1 was ab-
sent or reduced in mutant atria at E9.5 (Figure 7C and 7D). 
Expression of the atrial gene MLC2a did not seem to be 
affected in Tbx20 cKOs relative to controls (Figure 7F). 
Reduced COUP-TFII and Hey1 expression suggested per-
turbation of atrial identity in Tbx20 cKOs.
In myocardial knockouts of COUP-TFII, ventricular 
genes Hey2, Irx4, and MLC2v are upregulated in mutant 
atria at E14.5.46 We examined their expression in Tbx20 
cKOs (Figure 7C) and found that MLC2v was ectopically 
expressed in right atrium, although overall transcript levels 
in E9.5 or E11.5 hearts were not significantly altered as 
measured by qPCR. At E11.5, although Hey2 and Irx4 were 
not upregulated in Tbx20 cKO atria, Hey2 and Irx4 were 
reduced in Tbx20 cKO ventricles, which was confirmed 
by qPCR. Hey2 and Irx4 are important for regulation of a 
Figure 5. TBX20 (T-box 20) regulates cardiomyocyte proliferation genes. A, Quantitative polymerase chain reactionof genes associated with cell cycle 
and proliferation in control and Tbx20 cKO hearts (n=3–4 biological replicates; *P<0.05 Mann–Whitney U test). B, Mycn expression is reduced in ventricles 
and OFT of Tbx20 cKO at embryonic day (E) 9.5 and E11.5. C, Erbb2 expression is reduced in ventricles of Tbx20 cKO at E9.5 and E11.5. Bars: 0.2 mm. cKO 
indicates conditional knock out mutant.
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ventricular specific program.48,49 In summary, these results 
demonstrated that TBX20 plays a critical role in establish-
ing atrial and ventricular identity, potentially by direct reg-
ulation of genes required to execute atrial and ventricular 
gene programs.
TBX20 and COUP-TFII May Cooperate in Target 
Gene Regulation
To explore a potential regulatory interaction between TBX20 
and COUP-TFII, we compared putative direct targets of 
COUP-TFII and TBX20, using a previously published data set 
of COUP-TFII ChIP-Seq in embryonic atria.46 This analysis 
indicated minimal overlap between TBX20 and COUP-TFII 
binding (289 out of 5110 TBX20 ChIP-Seq peaks). These re-
gions are candidate enhancers that may be regulated by co-
operative binding of TBX20 and COUP-TFII. Intriguingly, 
however, we noted considerable overlap between putative 
direct TBX20 and COUP-TFII target genes, indicating that 
TBX20 and COUP-TFII may act on distinct enhancers to 
achieve regulation of shared downstream target genes (Onine 
Figure V). We next selected genes differentially expressed 
in Tbx20 cKO cardiomyocytes and found that among shared 
target genes were both upregulated and downregulated genes. 
Together, these data provide further insights into potential reg-
ulatory interactions between TBX20 and COUP-TFII during 
heart development.
Figure 6. TBX20 (T-box 20) regulates second heart field and cardiac development genes. A, Quantitative polymerase chain reaction of Isl1 (LIM/
homeodomain transcription factor Islet1), Bmp2 (bone morphogenetic protein 2), and Bmp10 (bone morphogenetic protein 10) in control and Tbx20 cKO 
cardiomyocytes (n=3–4 biological replicates; *P<0.05 Mann–Whitney U test) and BMP10 in control and Tbx20 cKO right atrial tissue (right; n=6; *, P<0.05) 
B and C, Proximal border of high Isl1 expression (arrow) is expanded from distal outflow tract toward right ventricle at E11.5 in Tbx20 cKO heart. D and E, 
Tbx5 expression is enhanced in Tbx20 cKO atria (ventral view). F and G, Bmp2 expression is expanded to atria in Tbx20 cKO heart (arrows). H and I, Bmp10 
is overexpressed in right atrium of Tbx20 cKO heart (arrow); B–E, H, and I, ventral view; F and G, dorsal view. Bars: 0.2 mm. cKO indicates conditional knock 
out mutant; and Tbx20, T-box 20.
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A COUP-TFII Enhancer Bound by TBX20 Drives 
Transgene Expression In Vivo
Because COUP-TFII was significantly downregulated in 
Tbx20 cKO cardiomyocytes, and as this reduced expression 
was likely to contribute to cardiac defects in our mutant mice, 
we further investigated direct regulation of COUP-TFII by 
TBX20. Scanning the COUP-TFII regulatory landscape, we 
identified 2 TBX20-binding sites by ChIP-Seq in mouse em-
bryonic hearts, one of which was also identified in adult heart 
(Figure 8A and the study by Shen et al19). Both sites were 
evolutionarily conserved and marked by enhancer-associated 
histone modifications including H3K4-methylation and 
H3K27-acetylation, as well as P300 binding in embryonic 
mouse hearts, suggestive that these regions correspond to 
cardiac enhancers.50 By inspection of the Human Epigenome 
Roadmap data,51 we noticed that orthologous human regions 
corresponding to these candidate enhancers also harbor epi-
genetic marks that are hallmarks of enhancers in human fe-
tal heart samples (Online Figure VI). To directly test the 
enhancer properties of these candidate regions, we used an 
in vivo mouse transgenic reporter assay. One of the regions 
tested resulted in consistent, robust reporter gene expression 
Figure 7. TBX20 (T-box 20) regulates chamber identity genes. A, COUP-TFII (chicken ovalbumin upstream promoter transcription factor 2) expression is 
downregulated in Tbx20 cKO hearts compared with control (n=3–4 biological replicates; P<0.05 Mann–Whitney U test). B, In situ hybridization for COUP-TFII 
at E9.5, E10.5, and E11.5 C, Quantitative polymerase chain reaction (qPCR) of chamber identity genes in control and Tbx20 cKO cardiomyocytes (n=3–4 
biological replicates; *P<0.05 Mann–Whitney U test). D, Hey1 expression is downregulated in atria (left), and Hey2 (middle) and Irx4 (right) are downregulated 
in ventricles of E9.5 Tbx20 cKO mutant. E, qPCR of Mlc2v gene expression in E9.5 and E11.5 hearts (n=3–4 biological replicates; not significant Mann–
Whitney U test). F, In situ hybridization shows comparable Mlc2a expression at E11.5 (left), comparable Mlc2v expression at E9.5 (middle), and ectopic 
Mlc2v expression in atria of Tbx20 cKO hearts at E11.5 (arrow, right). Bars: 0.2 mm. cKO indicates conditional knock out mutant.
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in multiple embryonic regions, including venous inflow area 
and atria in 4 out of 5 transgenic embryos (Figure 8C). Section 
analysis further revealed that enhancer 1 consistently drove 
reporter gene expression in atrial cardiomyocytes (4 out of 5 
transgenic embryos), including venous valve myocardium, 
recapitulating endogenous cardiac COUPTF-II expression. In 
contrast, no expression was observed in ventricular myocardi-
um, with the exception of a small patch of myocardial cells in 
Figure 8. TBX20 (T-box 20) binds and regulates an enhancer upstream of COUP-TFII (chicken ovalbumin upstream promoter transcription factor 
2) that drives expression in atrial cardiomyocytes. A, TBX20-GFP (green fluorescent protein) ChIP-Seq (chromatin immunoprecipitation with high throughput 
sequencing) of E11.5 mouse hearts in COUP-TFII genomic region. B, Magnification of enhancer 1 and schematic representation of reporter construct. C, COUP-
TFII enh1::lacZ embryo showing reporter gene expression in developing atrial myocardium (arrow) and venous inflow region (arrowhead). D, Section analysis of 
COUP-TFII enh1::lacZ transgenic embryo demonstrates X-gal staining in developing atrial myocardium (arrows) and caval vein (arrowheads). E, COUP-TFII enh1-
mutTBE::lacZ embryo showing loss of staining in atrial region and sustained expression in venous inflow region (arrowhead). F, COUP-TFII enh1-mutTBE::lacZ 
transgenic embryo demonstrates absence of X-gal staining in developing atrial myocardium (arrows). G, Overview of suggested regulatory pathways by which 
TBX20 determines chamber identity and cardiomyocyte development based on the current and previous studies. In outflow tract, TBX20 suppresses expression of 
second heart field (SHF) genes, including Isl1 (LIM/homeodomain transcription factor Islet1) and Fgf10 (fibroblast growth factor 10). In atria, TBX20 contributes to 
atrial specification by suppressing ventricular and atrioventricular canal genes Bmp2 (bone morphogenetic protein 2) and Bmp10 (bone morphogenetic protein 10), 
while activating COUP-TFII and Hey1 expression. In atrioventricular canal, TBX20 activates Bmp2 expression. In ventricles, TBX20 activates expression of Hey2 and 
Irx4. Furthermore, TBX20 regulates cardiomyocyte proliferation, via the activation of Mycn, Erbb2, and Cdc6. Bars: 0.2 mm, except for left figures in C and E: 1 mm.
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the right ventricle of a single transgenic embryo (not shown). 
To further confirm that expression of this COUP-TFII enhanc-
er in atrial myocardium was directly regulated by TBX20, 
we mutated a conserved TBX20 binding site within this en-
hancer and found that expression in atrial cardiomyocytes 
was largely abolished in transgenic embryos (no detectable 
LacZ [beta-galactosidase]-expressing atrial cardiomyocytes 
in 6 out of 7 transgenic embryos, with the remaining embryo 
having few scattered lacZ-expressing atrial cardiomyocytes; 
Figure 8D), while reporter gene expression outside the heart 
was observed in a pattern similar to that of the wild-type en-
hancer (4 out of 7 embryos; Figure 8D). We next established 
that this enhancer was functionally connected with COUP-
TFII. We performed a promoter-based capture chromosome 
conformation capture with high-throughput sequencing in in-
duced pluripotent stem cell–derived human cardiomyocytes to 
identify long-range physical interactions between genes and 
enhancers. We observed that this enhancer directly loops and 
contacts the COUP-TFII promoter, 140 kb away, confirming 
that this is a COUP-TFII enhancer (Online Figure VI). Taken 
together, these results linked TBX20 binding to an evolution-
ary conserved enhancer that regulates COUP-TFII expression 
in developing atrial cardiomyocytes, uncovering a mechanism 
by which COUP-TFII expression is TBX20 dependent. As 
discussed further below, decreased COUP-TFII expression is 
likely to contribute to several aspects of observed Tbx20 cKO 
phenotypes.
Discussion
Using global transcriptome analysis combined with em-
bryonic heart ChIP-Seq, we identified previously unrecog-
nized critical gene targets and cell autonomous functions 
of TBX20 in midgestation cardiomyocytes, illuminating 
a major role for TBX20 in establishing ventricular versus 
atrial identity and a particularly critical role in left atrial 
growth.
Mutations in TBX20 are associated with interventricular 
septal defects and atrioventricular septal defects.5,8,52 In previ-
ous studies, we showed that TBX20 is required in endothe-
lial lineages for interatrial and interventricular septation, via 
regulation of the extracellular matrix proteoglycan versican.17 
Here, we show that TBX20 is also required in cardiomyocytes 
for development of the atrial and interventricular septa, po-
tentially via the regulation of proliferation in these structures. 
Thus, TBX20 seems to be required in multiple cellular lin-
eages for cardiac septation.
Cell proliferation on the outer curvature of the heart be-
tween E9.5 and E12.5 makes major contributions to growth 
of chamber myocardium.10 Tbx20 global mutants exhibit 
decreased cardiomyocyte proliferation and arrest develop-
ment at E9.5, with severely hypoplastic, unlooped hearts.11–13 
Here, ablation of Tbx20 in developing cardiomyocytes led 
to failure of cardiac chamber expansion and septal defects, 
associated with reduced proliferation in Tbx20 cKO car-
diomyocytes. These results demonstrated for the first time 
a cell autonomous requirement for TBX20 in embryonic 
cardiomyocyte proliferation. Intriguingly, overexpression 
of TBX20 induces cardiomyocyte proliferation in adult 
cardiomyocytes.18
Previous work in global Tbx20 mutants indicated ectopic 
Tbx2 expression might contribute to proliferation defects.11–13 
However, studies with compound Tbx2;Tbx20 mutants show 
that additional pathways exist by which TBX20 regulates 
cardiomyocyte proliferation, independent of Tbx2.15 Here, 
intersection of RNA-Seq data and ChIP-Seq data gave new 
insights into additional mechanisms by which TBX20 cell au-
tonomously regulates myocyte proliferation. Genes that were 
differentially expressed, with TBX20 binding near promoter 
or cis-regulatory elements, were considered putative direct 
targets. However, we cannot formally rule out that gene ex-
pression changes are the consequence of anatomic changes 
in Tbx20 cKO hearts or reflect indirect regulation by TBX20. 
Further proof that genes identified here putative direct down-
stream targets of TBX20 would require experiments testing 
enhancer activity and dependence on TBX20 in vivo. Our data 
suggested that TBX20 directly activates many genes required 
to effect cardiomyocyte proliferation, including Mycn, Erbb2, 
and Cdc6. Recently, TBX20 mutations were associated with 
left ventricular noncompaction and decreased proliferation 
in human induced pluripotent stem cell–derived cardiomyo-
cytes, potentially via downregulation of the TGFB (trans-
forming growth factor beta) inhibitor PRDM16.9 In our study, 
PRDM16 was downregulated in embryonic cardiomyocytes 
on loss of TBX20, and we identified 4 TBX20-binding sites 
within the PRDM16 gene body in embryonic heart, providing 
further support for a direct regulatory role for TBX20 in de-
velopment of left ventricular noncompaction. Thus, our data 
shed new light on pathways by which TBX20 directly and cell 
autonomously regulates cardiomyocyte proliferation.
Cardiac chamber formation is marked by activation of a 
cardiomyocyte differentiation gene program in developing 
chamber myocardium, whreas nonchamber myocardium of 
the AVC, OFT, and inflow tract retains more primitive char-
acteristics.53 Multiple T-box genes play important roles in dif-
ferent aspects of this process. Previous studies using global 
Tbx20 mutants and in vitro assays have indicated that TBX20 
and TBX5 cooperate with NKX2.5 and GATA4 to promote 
chamber differentiation via activating Nppa and Gja5 expres-
sion.3,23,33,54,55 In addition, within chambers, TBX20 represses 
non–chamber-specific genes, such as Tbx2.11–13,15 In AVC, 
TBX2 represses chamber-specific gene expression to main-
tain the less differentiated, nonchamber myocardial fate. Tbx2 
expression in AVC is activated by BMP2.36,37,56 Here, we pro-
vided evidence to suggest that TBX20 directly suppressed 
Bmp2 expression in developing atrial cardiomyocytes, result-
ing in ectopic Bmp2 expression in Tbx20 cKOs. Ectopic Bmp2 
expression in Tbx20 cKO atria may also result from reduced 
expression of putative TBX20 direct targets Hey1 and Hey2, 
as Hey1 and Hey2 restrict expression of Bmp2 and Tbx2 to the 
AVC.57 Altogether, our studies demonstrated that TBX20 cell 
autonomously promotes chamber myocardial fate by suppres-
sion of an AVC gene program in chamber myocardium.
RNA-Seq of Tbx20 cKO cardiomyocytes revealed in-
creased expression of cardiac progenitor markers Isl1, Fgf10, 
and Hopx compared with littermate controls.30,32,58 Notably, 
these genes were also predicted direct targets of TBX20 in em-
bryonic hearts. Isl1 is necessary for a subset of undifferentiat-
ed cardiac progenitors of the second heart field to proliferate, 
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survive, and migrate.30 Isl1 is downregulated in OFT when 
cardiac progenitors enter the heart and differentiate. TBX20 
has been shown to directly repress Isl1 in E8.5 myocardium.12 
Our studies demonstrated an ongoing requirement for TBX20 
to repress Isl1 in E11.5 cardiomyocytes. Fgf10 overexpression 
in E11.5 Tbx20 cKO cardiomyocytes as measured by RNA-
Seq and qPCR could not be confirmed by whole mount RNA 
in situ studies, perhaps because of the lower sensitivity of the 
RNA in situ assay.
Although proliferation of both atria was significantly re-
duced in Tbx20 cKOs, left atrial proliferation was more dras-
tically affected than right atrial proliferation. We examined 
Pitx2 expression but found no difference in expression that 
could explain this phenotype. Left atrial hypoplasia along 
with other cardiac defects was found in a stillborn baby with 
a 15q26.2 deletion that includes COUP-TFII.59 Patients with 
similar 15q26.2 deletion but intact COUP-TFII do not show 
cardiac defects. Moreover, a mouse COUP-TFII hypomorphic 
mutant exhibits left atrial hypoplasia,60 and our Tbx20 cKO 
mutants display significant reductions in COUP-TFII expres-
sion. Therefore, COUP-TFII insufficiency may underlie the 
left atrial hypoplasia in Tbx20 cKOs.
Atrial and ventricular chambers have unique roles 
in effecting blood circulation.61–63 Intersection of Tbx20 
cKO RNA-Seq and TBX20-GFP ChIP-Seq data illumi-
nated important cell autonomous roles and mechanisms by 
which TBX20 sets up both atrial and ventricular identity 
(Figure 8G). Notably, COUP-TFII was a direct target of 
TBX20. COUP-TFII is an orphan nuclear receptor essential 
for establishment and maintenance of atrial identity.46 During 
heart development, COUP-TFII is selectively expressed in 
atrial, not ventricular, myocardium.64 Cardiomyocyte loss of 
COUP-TFII leads to reduced atrial gene expression and ven-
tricularization of atria.46 In keeping with this, in Tbx20 cKOs, 
reduced expression of COUP-TFII in both atria was accom-
panied by reduced expression of the atrial gene Hey1, and 
ectopic atrial expression of the ventricular marker Mlc2v. 
Previous in vitro studies have described factors regulating 
COUP-TFII expression in other contexts.65–67 Our work has 
identified TBX20 as a direct regulator of COUP-TFII dur-
ing cardiogenesis in vivo. In addition to its critical role in 
atrial development and identity, our studies provide evidence 
indicating that TBX20 establishes ventricular identity by di-
rect regulation of Hey2 and Irx4 in developing ventricular 
myocytes.48,49
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